The increase in operating expenses year over year was primarily driven by a $2.3 million increase in sales and marketing expenses due to new hires added to our Lymphedema sales team, along with increased travel-related expenses as we return to normalized business activities.

Feb 21, 2023 / CFO / receipt, needs a key / Brent Moen, CFO | earnings call 2023-02-21 | transcript b350df0c-36e8-49e6-a0be-b47ccf499deb | chars 17520-17795 | segment 16

The increase in operating expenses year over year was primarily driven by a $4.4 million increase in sales and marketing expenses, largely due to the addition of our AfloVest sales team and new hires added to our Lymphedema sales team, along with increased travel and related expenses as we return to normalized business activities.

Nov 7, 2022 / CFO / receipt, needs a key / Brent Moen, CFO | earnings call 2022-11-07 | transcript c2dba02a-ac61-4261-841d-4dc7cbbc70b4 | chars 15507-15839 | segment 15

The increase in operating expenses was driven primarily by a $5 million, or 26 percent, increase in sales and marketing expenses, largely due to increases in personnel-related compensation expense, including the addition of the AfloVest sales team, and travel-related expenses as we return to hosting in-person regional sales meetings.

Feb 22, 2022 / CFO / receipt, needs a key / Brent Moen, CFO | earnings call 2022-02-22 | transcript c12ca097-9652-46ac-8156-3decfca45987 | chars 9964-10299 | segment 10

The year-over-year increase in operating expenses was driven primarily by a $2.7 million, or 14%, increase in sales and marketing expenses primarily due to increases in personnel-related compensation expense and travel-related expenses as we return to hosting in-person regional sales meetings.

Nov 8, 2021 / CFO / receipt, needs a key / Brent Moen, CFO | earnings call 2021-11-08 | transcript cb775128-5d95-424b-b1cc-8c38902b1073 | chars 13526-13820 | segment 13